Pharmaceutical major Cipla has attracted mixed sentiment from leading brokerages following developments around its Ventolin business, with analysts expressing caution over execution challenges despite acknowledging growth potential.
Morgan Stanley has held its Underweight rating on the stock while marginally increasing its price target to Rs 1,237 from the previous Rs 1,211. The brokerage’s cautious stance reflects concerns about the company’s ability to capitalize on the Ventolin opportunity, despite recognizing its significance.
In contrast, Citigroup maintains a more optimistic view, reiterating its Buy rating with a notably higher price target of Rs 1,530. This divergence underscores the market’s differing assessments of Cipla’s execution capabilities in leveraging the Ventolin portfolio expansion.
The Ventolin boost represents a meaningful development for Cipla, historically a major player in respiratory care. However, brokerages remain divided on whether the company can effectively execute on this opportunity amid competitive pressures and operational complexities in the respiratory segment.
Investors tracking Cipla on NSE/BSE should note this variance in analyst outlooks. The stock’s performance will likely hinge on management’s ability to demonstrate strong execution in integrating and growing the Ventolin business while maintaining profitability.
Source: Read original